Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803644 | 0.81 | CNR2 (0.54) | CNR2PSMB8PSMB5POLBMEN1 | |
| SCHEMBL27475409 | 0.79 | PSMB8 (0.61) | CNR2PSMB8PSMB5POLBMEN1 | |
| SCHEMBL28045696 | 0.78 | CNR2 (0.51) | CNR2PSMB8PSMB5POLBCNR1 | |
| SCHEMBL10795761 | 0.78 | CTSC (0.64) | CTSC | |
| SCHEMBL7296396 | 0.78 | CTRB1 (0.50) | — | |
| SCHEMBL8458841 | 0.78 | CTRB1 (0.50) | — | |
| SCHEMBL21724309 | 0.78 | SLC1A2 (0.45) | — | |
| SCHEMBL16908009 | 0.78 | CNR2 (0.54) | CNR2PSMB8PSMB5POLBMEN1 | |
| SCHEMBL5283197 | 0.78 | ALDH1A1 (0.61) | CNR2PSMB8PSMB5POLBMEN1 | |
| SCHEMBL5277278 | 0.78 | ALDH1A1 (0.61) | CNR2PSMB8PSMB5POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | claimed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | CNR2 3333/4885PSMB8 2318/4885PSMB5 2815/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | CNR2 3333/4885PSMB8 2318/4885PSMB5 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.